Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Wednesday, June 20, 2018 · 452,373,072 Articles · 3+ Million Readers

Hana Biosciences Completes Enrollment in Pivotal Phase 2 rALLy Clinical Trial of Marqibo

December 4, 2009 (FinancialWire) — Hana Biosciences (OTCBB: HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, has completed enrollment of its pivotal Phase 2 rALLy clinical trial for Marqibo(R) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia in second relapse, enrolling a total of 65 patients.

The company chose to exceed its enrollment target of 56 subjects, which was reached in August 2009, to collect a more robust pharmacokinetic data set in the adult ALL patient population. Patients have been enrolled and dosed at 22 sites in the United States, Canada, Germany, and Israel.

In June, during the 44th Annual American Society of Clinical Oncology Meeting, Hana announced preliminary data from the Phase 2 rALLy clinical trial, which showed encouraging anti-leukemic activity in a relapsed/refractory adult ALL patient population, enabling several patients to receive a potentially curative stem cell transplant. Data presented at ASCO also showed encouraging preliminary response duration and overall survival data, as well as a predictable safety profile with no unexpected toxicity.

The primary objective of the pivotal Phase 2 rALLy clinical trial is to assess the efficacy of single-agent, weekly Marqibo (2.25 mg/m2) with dosing based on actual body surface area without the dose capping applied to standard vincristine. Secondary objectives include evaluation of safety, response duration, and survival. The study population is defined as Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site ( Contact FinancialWire(tm) directly via

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (

Powered by EIN Presswire